story of the week
Efficacy and Safety of Adjuvant Nivolumab in Patients With Completely Resected Merkel Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial
Lancet 2023 Jul 11;[EPub Ahead of Print], JC Becker, S Ugurel, U Leiter, F Meier, R Gutzmer, S Haferkamp, L Zimmer, E Livingstone, TK Eigentler, A Hauschild, F Kiecker, JC Hassel, P Mohr, M Fluck, I Thomas, M Garzarolli, I Grimmelmann, K Drexler, AN Spillner, S Eckhardt, D SchadendorfFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.